Release issued 11th August 2008

Decision Resources introduces the only healthcare analytics tool that assesses the number of insured patients who have a specific disease, but are untreated

August 11, 2008-Waltham, Mass.-Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Florida has the highest number of untreated people with type 2 diabetes who also have prescription (Rx) drug coverage. This type of information is invaluable to pharmaceutical companies who are challenged to pinpoint the areas of greatest need for their drugs.

The new analytic tool from Decision Resources entitled "PatientFinder: Type 2 Diabetes" also reveals that West Virginia and Maine have the highest type 2 diabetes prevalence as a percent of their population. The report also finds that California has the absolute largest number of untreated patients (455 000) in part because it has the largest overall population. But the fact that California has a lower percentage of its population with Rx drug coverage means that the overall opportunity for market expansion in this state is less than in other, smaller states.

Why Pharmaceutical Companies Need this Information?
With the type of information included in PatientFinder, pharmaceutical organizations can identify the local markets that offer the greatest opportunity for their branded drug. Companies can identify markets that are underserved and determine if they should increase direct-to-consumer advertising, work with the local managed care organizations to increase awareness of the disease and benefits of their drug or align sales representatives to maximize market potential.

About PatientFinder
PatientFinder is the only healthcare analytics tool that assesses local markets for expansion opportunity by determining the number of insured patients in each territory who have the disease but are untreated. PatientFinder covers each of the 50 U.S. states and 318 U.S. metropolitan statistical areas (MSAs) and provides:

• Disease-specific prevalence numbers for each U.S. state and MSA
• Examination of treatment rates for the disease population to create percent treated and percent untreated estimates by state and MSA
• Unique analysis of the untreated population examined through a filter of Rx benefit coverage. The end result is an estimate of how many patients are untreated but can afford therapy within each territory-the true local measure of opportunity for pharmaceutical companies

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

(2nd December 2008) Market for cellular therapies will grow at a robust annual rate of more than 30 percent in the United States through 2017

(2nd December 2008) Biologic drugs, particularly Centocor/Janssen-Cilag's Stelara and Abbott/Eisai’s Humira, will drive the Psoriasis drug market to US$5 billion by 2017

(1st December 2008) Humira will overtake Remicade as the Crohn’s Disease market leader by 2012

(1st December 2008) Advair’s patient share in newly diagnosed Asthma patients is declining

(19th November 2008) Uptake of next-generation antifungals has intensified competition in the severe fungal infections drug market